Abstract: Recent advances in cytotoxic therapies for pancreatic ductal adenocarcinoma (PDA) are overshadowed by stalled clinical progress of more targeted strategies, the vast majority of which have failed in clinical trials. Inability to translate preclinical promise into clinical efficacy derives, in part, from imperfect disease modeling and mismatches between preclinical and clinical study design and execution. Into these gaps fall our patients who enter the clinical trial landscape expectantly and bear the brunt of its inadequacies. If improving patient survival is paramount, then it must be acknowledged that the failure of a phase III trial represents a larger failure of all of the work that preceded it. Repeated failures suggest a need to reappraise the current preclinical-to-clinical apparatus. Exceptional models of PDA are now available to researchers, and the first steps toward a new era of success can begin with improved selection and application of these systems. We discuss the key features of the major preclinical platforms for PDA and propose a paradigm for rigorous interrogation of prospective therapies.
BIOLOGICAL AND CLINICAL CHALLENGES OF PANCREATIC DUCTAL ADENOCARCINOMA
Pancreatic ductal adenocarcinoma (PDA), perhaps more than any other cancer, epitomizes the concept of a "neo-organ" because of the complex reorganization and composition of its tumor architecture and extracellular matrix (ECM). The microenvironment in PDA comprises a diverse array of cell types and ECM components that work in concert to create a unique physical, biochemical, and immunologic sanctuary for the malignant epithelium, which orchestrates the composition of this niche despite constituting a small fraction of the tumor mass.
1,2 Coopted fibroblasts and immune cells, including myeloid-derived suppressor cells and tumor-associated macrophages, are the predominant cell types found in PDA, 3, 4 but most tumors are nevertheless hypocellular and contain an intense desmoplastic matrix consisting of collagens, 5, 6 hyaluronan (HA) and other glycosaminoglycans, 7, 8 mucins, 9 and a slew of secreted enzymes, 10 signaling peptides, 11, 12 nucleic acid, 13, 14 and cellular detritus. [15] [16] [17] [18] Most of these cellular and extracellular components help sustain the nascent neoplasm.
The complex biology and physiology of PDA expose the inadequacies in any experimental platform that fails to model them accurately. There is an inherent tension between the necessarily reductionist approach of the scientific method and the need to adequately capture and convey the complex physiology of this multicellular malignancy in order to render experimentation clinically meaningful. Where precisely on the spectrum between these two seemingly conflicting imperatives a given model system lies will determine its suitability for a particular application. Ultimately, selection of a model depends on the question(s) being asked, but the closest possible recapitulation of the tumor composition and environment is likely to yield the most relevant data with the greatest potential for translation ( Fig. 1) .
The vast majority of therapies brought forward to PDA clinical trials have failed, 19 despite extensive knowledge and characterization of the genomic events and activated or disabled signaling pathways that initiate and support malignancy. These failures derive, in no small part, from the failure to fully account for the whole PDA neo-organ in preclinical experimentation. [20] [21] [22] [23] [24] [25] [26] [27] Modest gains have recently been made in palliative chemotherapy, 28, 29 but the development of more rationally designed, targeted therapies has lagged. This extensive history of clinical failures in PDA begins with inaccurate disease modeling in preclinical studies, which will doom a translational effort from the outset.
In acknowledging these failures and beginning to account for the compositional and organizational complexity of PDA, promising new targets and strategies have more recently emerged that consider the entire sanctuary rather than only the tumor epithelium. For instance, we now appreciate that high interstitial gel-fluid pressures derived from inordinate HA deposition can collapse blood vessels and impede perfusion of chemotherapy 7 ; targeted degradation of HA with pegylated hyaluronidase (PEGPH20) reopens blood vessels in the tumor to improve drug entry and effect, increasing disease-free survival in patients whose tumors have abundant HA. 30, 31 Indeed, the inability to achieve therapeutic concentrations may have doomed many drugs to "fail" in PDA, regardless of the target. Similarly, a deeper understanding of the actual mechanism behind the failure of immunity to contain PDA has led to strategies such as targeting myeloid-derived suppressor cells and other immunosuppressive populations to activate endogenous immunity or potentiate adoptive immunotherapy against PDA. 4, 32 Combining these and other novel strategies to disable the formidable tumor defenses could generate sustained responses, and possibly even cures, in PDA.
Several new and established models are accessible to researchers; all have a purpose, but alone, none may be sufficient to reliably bridge the gap between basic research and clinical therapy. The objective of this review is to examine the available models and their respective utilities for identifying and advancing effective therapies to the clinic.
PANCREAS CANCER MODELS Tumor Cell Lines
The earliest models available to pancreas cancer researchers were immortalized cell lines derived from patient tumors, ascites, or metastatic deposits. A number of lines were generated by various laboratories throughout the 1970s, 1980s, and 1990s and continue to be widely used to study PDA. [33] [34] [35] [36] [37] These cell lines have helped define the mutational spectrum seen in PDA and, in particular, the cardinal genetic events driving tumorigenesis including KRAS activation, TP53 mutation, SMAD4 deletion, and CDKN2A silencing. 38, 39 However, accumulating experience with their most common application in 2-dimensional culture has revealed that they are insufficiently representative of PDA tumors, and an abundance of caution should accompany any interpretations of treatment efficacy. Changing the "vessel" in which the cells are grown through either heterotopic or orthotopic xenotransplantation of these lines into immunocompromised animals only marginally improves their fidelity. The tumor "mass" in these experiments still lacks the fundamental characteristics of autochthonous PDA, namely, an abundant stromal infiltration of immune cell subsets and their spatial organization, a complex matrix deposition, and unique vasculature and perfusion properties. 40 Despite their continued use, the almost invariant failure of clinical trials predicated on experimentation with these systems is undeniable.
That is not to say that these cell lines are without value, only that their use is limited. They are readily attainable, affordable easy to work with and manipulate, and can yield results quickly, making them suitable for genomic analyses and basic studies of signaling pathways and biochemical properties. For example, they have been used effectively to study KRAS signaling pathways, protein-protein interactions, identification of drug targets, and other aspects of PDA biology. [41] [42] [43] [44] Insights gleaned from such studies can provide a platform for hypothesis-driven experimentation in higher-order models, such as patient-derived xenografts (PDXs), organoids, or genetically engineered mouse models (GEMMs), but they should not be used alone or even as a primary justification for advancing strategies into the clinic.
Organoids and Patient-Derived Xenografts
Organoid and PDX models share many features, most notably the ability to study a specific patient's tumor contemporaneously and potentially impact their clinical management. Organoids are formed by 3-dimensional culture of digested tumor tissues, whereas PDXs are generated by implantation of tumor tissue fragments into immune-compromised mice. Both are derived ideally from freshly excised tissues at the time of surgery, and these models may therefore not be readily accessible to all researchers (these preparations may survive freeze/thaw procedures, however, and therefore be amenable to transport for wider use). Once a pipeline to patient tissue is established, propagation and analyses of these models afford researchers and clinicians the opportunity to develop personalized therapies for individual patients, albeit with considerable caveats.
The study of cells grown in 3 rather than 2 dimensions has been championed for several decades, and early structures derived from digested normal tissues were originally called "organoids" because of their ability to reflect in vitro the organization and behavior of the epithelium in the source organ. [45] [46] [47] [48] [49] [50] Compared with PDXs, single-cell suspensions of human tumors grown as organoid cultures are ostensibly more economical and can be more rapidly established and expanded, increasing the likelihood to inform the ongoing management of the patient from which they were derived. The digested primary cell suspensions are grown as spheroids embedded in Matrigel with media supplemented by a variety of exogenous growth factors, hormones, and nutrients sufficient to support the survival and proliferation of tumor cells and, in some cases, normal cells. 51 The requirement for specific growth conditions and matrix constituents, especially Matrigel, in organoid cultures contributes substantially to their cost, while also potentially altering their fidelity to the native tissues. Although organoid cultures of PDA have been shown to retain characteristics of the original tumor epithelium during their implantation and propagation into host animals, 52 they necessarily lack the full architectural and compositional context of PDA, particularly the immune cells and ECM constituents that so dramatically influence disease biology and therapeutic response. Thus, given the limited extent to which they recapitulate the organization and behavior of the pancreas cancer neo-organ, the term "organoid" may be too liberal. Questions of nomenclature aside, 53 efforts are ongoing to attempt to restore at least some elements of the PDA stroma that are lost during the generation of these structures. 54 This will require finding ways not only to enable these nontransformed cells to survive under shared conditions with the malignant epithelium, but also to reconstitute the spatial and functional relationships among the various cell types found in the native tumor (i.e., fibroblast subsets, multiple myeloid cell subtypes, paracrine signaling pathways, complex glycosaminoglycan-and collagen-rich ECM, etc.) that may profoundly influence disease biology and drug response. In addition, because the tumor tissues must be sampled locally and the organoids appear to grow clonally from single cells of origin, the breadth of intratumoral heterogeneity may be limited or distorted, further challenging their translational potential. 52 For the moment, these remain open-ended questions that can be directly tested. At present, there are no reports of directly translating a strategy to a given patient's management, but organoid systems do hold considerable translational promise.
Compared with conventional xenografts or organoids, PDX models may better approximate the original tumor architecture and composition, at least in early passages. The attendant fibroblasts, immune cells, and other nontransformed cells are transplanted en masse with the tumor epithelial cells, although they eventually die out and are replaced, to some extent, by their murine counterparts-with the notable exception of adaptive immunity. To prevent graft rejection, PDX implantations are necessarily performed in host mice that lack functional B and T cells (e.g., TCR/Ig-deficient NOD SCID or Rag-deficient mice) or have even higher-order immunodeficiency (e.g., NSG or NRG mice that lack B and T cells as well as interleukin 2 receptor γ). [55] [56] [57] These host deficiencies substantially increase the engraftment rate at the expense of functional immunity, which is an important consideration in defining response to therapy. 3, 4, 58 To address this shortcoming, coengraftment of the patient's hematopoietic stem cells can reconstitute a more relevant immune contexture and perhaps more accurately model the disease. [59] [60] [61] [62] [63] Such humanized mouse models are expensive, however, and slow to develop and are thus less likely to benefit the original patient. A series of PDXs derived from defined subsets of patients could nevertheless be used to generate a representative and informative screening platform for preclinical evaluations of drug action and efficacy. [64] [65] [66] [67] The promise of organoid cultures and PDX models lies in the ability to practice personalized medicine. Indeed, tailored regimens have been identified and tested in organoid and PDX systems that underscore their potential to inform personalized therapy of PDA. 52, 68, 69 However, it is unclear whether in vivo drug screens of organoid or PDX implants, in vitro drug sensitivity assays, mutational analyses, and/or other related investigations will define patient-specific treatments that could rapidly be administered under the current regulatory principles imposed by the clinical trial system. Personalized clinical management using these model systems will require the establishment and navigation of unproven "n = 1" trials and potentially necessitate an unprecedented ability to treat with investigational agents (largely because novel combinations may be suggested by such experiments that have not previously been tested in humans). The promising preclinical results with these platforms, coupled with the dire prognosis of PDA, provide both proof of principle and sufficient impetus to justify finding such a path. Moreover, to the extent that such strategies promote an empiric, mutation-agnostic approach, they also address the unavoidable reality that we have known the cardinal drivers and modifiers of PDA (i.e., KRAS, TP53, INK4A, SMAD4, etc.) for decades and yet still cannot effectively treat patients based on the status of these particular genes. The question remains whether a deeper personalization of therapeutic strategies can be effectual without greater advancements in the treatment of PDA as a whole. In this respect, organoid and PDX models have great potential for the personalization of treatment, but are perhaps less suitable for broad efficacy testing of novel therapeutics because of the difficulty in generating these models and the incomplete recapitulation of the whole tumor in situ.
Genetically Engineered Mouse Models
The development of highly faithful GEMMs has transformed the field of pancreas cancer research as well as our understanding of disease pathogenesis. 70, 71 Critical and previously unanticipated insights into the biological and mechanical properties of the tumor, the evolution of the immune response, and the influences of individual and specific combinations of gene mutations on disease behavior have all emerged from studies in GEMMs. Genetically engineered mouse models arguably represent the current standard for preclinical testing of therapeutic strategies in pancreas cancer and provide several advantages by modeling autochthonous PDA tumorigenesis and progression with faithful representation of the context, composition, and organization of PDA in an immunocompetent animal.
Numerous distinct GEMMs for PDA have now been developed and characterized, all predicated on the original "KC" model, in which an oncogenic Kras G12D point mutation introduced at the endogenous locus is conditionally expressed by Pdx1-or p48-Cre, resulting in pancreas-specific expression of mutant Kras at physiological levels. 72 Expression of physiological levels of oncogenic Kras results in increased activated (i.e., GTP-bound) Kras, increased engagement of effector pathways within the cells, and increased proliferation; this contrasts with overexpressed oncogenic Ras, which instead induces widespread senescence in the absence of cooperating tumor suppressor gene mutations. [73] [74] [75] The KC model of PDA substantiated oncogenic Kras as the principal initiating event in pancreas cancer, 72 and subsequent models have elucidated how concomitant mutation of each of the cardinal tumor suppressor genes shapes the resulting disease initiated by activated Kras. Specifically, investigations of the effects of Trp53 mutation or deletion, 76, 77 Smad4 deletion, 78 and Ink4a/Arf deletion 79 revealed accelerated tumorigenesis in each case, albeit to differing extents and with very different clinical courses of disease progression. Whereas KPC mice, with concurrent Kras and Trp53 mutations, progress through pancreatic intraepithelial neoplasia to widely metastatic PDA, mutation of Kras engineered together with early homozygous Smad4 deletion (KDDC) followed by later spontaneous mutation of Trp53 or Ink4a instead produces mucinous cystic neoplasms as a precursor to PDA with an attenuated metastatic potential. 78 Simultaneous mutation of Trp53 and heterozygous loss of Smad4, the KPDC model for PDA, revert the phenotype back to pancreatic intraepithelial neoplasia-to-PDA progression albeit with minimal metastatic proclivity. 80 In contrast, tumors from KIIC mice (incorporating homozygous deletion of the combined Ink4a/Arf loci) proliferate rapidly such that mice succumb to primary disease burden by 12 weeks in the absence of appreciable macrometastatic disease. 79 Further combinations of these and other gene alterations have led to additional PDA GEMMs, 12, [81] [82] [83] [84] [85] including models of an alternative precursor to PDA, intraductal papillary mucinous neoplasms, through Tgfa overexpression or Gnas mutation. 86, 87 Importantly, these GEMMs also expand our capabilities for the development of related models; the tumors that develop in these GEMMs are highly amenable to in vitro culture, and GEMMderived cell lines or organoids can be orthotopically implanted into syngeneic mice to yield an alternative implantation model that retains immune compartment infiltration and behavior. Such syngeneic models further enable exploitation of genetic manipulation in vitro and provide a high-fidelity model for focal disease in vivo.
Many PDA GEMMs are now available, but not all are equally representative of the human disease. For instance, notable differences in PDA pathology, particularly with regard to metastatic burden, have been described with point mutation compared with targeted deletion of Trp53 in the context of oncogenic Kras expression, 88 and point mutation of TP53 followed by loss of heterozygosity is more common in human PDA than simple biallelic TP53 deletion or silencing. 89 Exactly why is unknown, but it suggests that the mutant TP53 protein, which in fact accumulates after loss of heterozygosity rather than disappears as occurs with biallelic loss, exerts its own influence on disease progression that is not represented by loss of Trp53 in GEMMs of PDA. [90] [91] [92] [93] [94] [95] [96] Even more subtly, PDA initiated in the pancreas by Pdx1-Cre expression may differ from that initiated by p48
Cre and/or other cell compartments expressing Cre recombinase that are also used to target these mutations to the pancreas. 97 There may also be differences in embryonic versus adult activation of the alleles, although this has not yet been established. These widely divergent presentations necessitate careful consideration of which GEMM is most appropriate for a given preclinical study; enrolling KIIC mice, for example, in a study where metastasis is an important endpoint would be less useful, and use of the KDDC model should be restricted to studies focused on the specific mucinous cystic neoplasmto-PDA phenotype.
An important feature of these GEMMs is the ability to manifest intratumoral and intertumoral variability. Although GEMMs are derived from inbred strains, specific cohorts can exhibit a wide range of disease presentations and histopathologies. As an example, despite the conserved background genetics and focused combinations of cardinal mutations, we have consistently observed low-frequency passenger mutations in coding and noncoding regions of DNA from epithelial cells isolated from several GEMM PDA (unpublished observations), which parallels the relatively low incidence of stochastic passenger mutations in human PDA but may nevertheless influence cell behavior and disease progression. Even within an individual mouse, multiple unrelated clones can progress to invasive disease as a result of the inherent multifocality of the targeting strategy. In some instances, this disease multifocality may also complicate interpretations of the experimental outcomes, by obscuring a potential survival benefit of a therapy, for instance, or preventing investigations of resectable disease; however, the same realities may also confer increased stringency in subjecting a given therapy to a greater number of potentially divergent clones. An increasingly important feature of these models is the presence of intact immunity, which is critical to the assessment of newer generations of immune-modulatory drugs and/or adoptive T-cell strategies and even seemingly unrelated therapies that may influence immune composition and response in unanticipated ways.
Overall, these autochthonous models phenocopy the spectrum of human PDA remarkably well with regard to tumor architecture, composition, biological and clinical behaviors, and, most importantly, therapeutic response. Indeed, the tumors arising in GEMMs also capture perhaps the most salient feature of the human disease-they are extremely difficult to treat. Although the rigorous assessment of therapies in GEMMs can be challenging and expensive and take longer to mature than the aforementioned models, the reward may be a more accurate platform for vetting the clinical efficacy of prospective treatments. Genetically engineered mouse models also permit simultaneous assessment of numerous pertinent endpoints and phenotypes (e.g., tumorigenesis, survival, metastasis, multiclonality, etc.). The potential for GEMMs in advancing PDA therapies is demonstrated by the development of PEGPH20 for enhancing tumoral delivery of cytotoxics, originally tested in the KPC model, which has shown promise in clinical trials for HA-high PDA patients.
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DESIGNING PRECLINICAL STUDIES OF PDA
Effective preclinical development of treatment strategies requires a confluence of research with distinct model systems to elucidate potential targets, mechanisms of action, therapeutic response, and off-target effects. Given the particularly poor success rate of clinical trials in PDA, it is apparent that the current standard for vetting prospective therapies is insufficient. Patients with PDA frequently have only one shot at treatment; thus, each imperfectly designed clinical trial not only fails the patient, but it also can detract critically from better-designed trials. A coordinated effort among researchers, clinicians, pharmaceutical companies, and patient advocates should be focused toward choosing model systems appropriately, as described previously, and designing preclinical experimentation with the clinic in mind. The failure of therapeutic strategies in preclinical stages should be expected and accepted; this mirrors the reality of the clinic, and an honest, unbiased interpretation of negative, equivocal, or at best marginal results could save valuable resources that would be better applied elsewhere. 19 One recent example of a clinical failure highlights the potentially devastating consequences of incongruity between the imperatives in the preclinical and clinical spheres: the unexpected early closure of a phase IB/2 clinical trial of the Smoothened inhibitor IPI-926, because of shortened survival in the experimental arm. In this case, the initial preclinical studies provided important proof-of-principle concepts regarding general barriers to treatment in PDA; however, the studies did not use a treatment schedule, route of administration, and duration that were representative of actual clinical practice. 99 Thus, the clinical trial used the agent differently than the preclinical study. Subsequent reassessment of the inhibitor in the same GEMMs with adjustments to these parameters recapitulated the decreased efficacy and increased disease aggressiveness observed in the clinical trial and revealed insights into the mechanism of failure. 12 Thus, even when an appropriate model system is chosen, it must also be applied correctly.
We have attempted to incorporate these principles into a Murine Clinical Trials Program (MCTP) modeled on the structure and execution of clinical trials (Fig. 2) . The foundation for the MCTP is the KPC mouse, although other related GEMMs (i.e., KC, KDDC, KPDC etc.) are incorporated into investigations with specific goals. Therapeutic strategies to be tested in the MCTP are gleaned and winnowed from a variety of sources including our own work and the published literature, and dosing regimens and schedules are based on results from previous clinical trials or determined empirically, maintaining routes of administration used in patients. A combination of clinical and tissue-based endpoints is used to identify regimens likely to have maximal impact in the clinic. KPC mice are bred, aged, followed clinically by physical examination, and screened by abdominal ultrasound; they are enrolled into randomized, blinded pilot studies when the primary tumors reach 3 to 6 mm in size. The pilot studies generally consist of 5 to 6 study mice per arm plus controls. Animals are sacrificed at treatment day 14 or 28 and assessed for objective response (by ultrasound), apoptosis and proliferation of epithelial and other cell compartments, fibroblast content and activation state, immune infiltration and activity, vascular architecture, interstitial pressures, and matrix composition. These studies are designed to rapidly interrogate strategies and select those that are most likely to produce meaningful effects in the clinic. Strategies are advanced to large, full-scale survival studies when predetermined endpoint(s) assessed at day 14 and/or day 28 would extrapolate to improving survival by 50% or more, an appropriately ambitious goal. Strategies that do not produce such substantial effects after 28 days are abandoned.
Survival studies are randomized, blinded, and placebo controlled and typically consist of arms containing 20+ KPC mice with the same enrollment criteria as described above. The studies include a standard treatment arm (typically gemcitabine or gemcitabine + nab-paclitaxel) and the standard regimen plus the investigational agent(s). These studies are designed to assess the most meaningful endpoint, survival, while also examining for unanticipated sequelae of long-term treatment with investigational agents. Treatment is given in cycles of 3 weeks "on" and 1 week "off," as typically done with PDA patients, until the animals become symptomatic, at which point an extensive battery of endpoints are assessed. To increase the likelihood of success in patients, we set the bar high in these murine studies by considering only those therapies that increase median survival by 50% or more in the MCTP to be worthy of further pursuit. The strategy is admittedly time and resource intensive, but we propose that the increased likelihood of ultimate success, as well as the early abandonment of strategies destined to fail, is worth these upfront investments.
CONCLUSIONS
Developing effective therapies against pancreatic cancer has proven to be especially arduous. A new understanding of the complex relationships between malignant and nonmalignant elements in the pancreas cancer neo-organ has greatly expanded the scope of potential therapeutic targets. A growing repertoire of highfidelity model systems and experimental platforms raises tenable hope that we will be able to navigate this new landscape productively, interrogating novel strategies rationally and systematically for translation to the clinic. The challenges ahead include choosing the correct model system for the question(s) being asked and applying the knowledge gained to the appropriate clinical context. Success will be measured in meaningfully improving the quality of life and survival of our patients.
